R
Richard G. Langley
Researcher at Dalhousie University
Publications - 231
Citations - 19456
Richard G. Langley is an academic researcher from Dalhousie University. The author has contributed to research in topics: Psoriasis & Psoriasis Area and Severity Index. The author has an hindex of 62, co-authored 207 publications receiving 16927 citations. Previous affiliations of Richard G. Langley include University of California, San Diego & Harvard University.
Papers
More filters
Journal ArticleDOI
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley,Boni E. Elewski,Mark Lebwohl,Kristian Reich,Christopher E.M. Griffiths,Kim A. Papp,Lluís Puig,Hidemi Nakagawa,Lynda Spelman,Bárður Sigurgeirsson,Enrique Rivas,Tsen-Fang Tsai,Norman Wasel,Stephen K. Tyring,Thomas Salko,Isabelle Hampele,Marianne Notter,Alexander Karpov,Silvia Helou,Charis Papavassilis +19 more
TL;DR: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Journal ArticleDOI
Psoriasis: epidemiology, clinical features, and quality of life
TL;DR: The epidemiology, clinical features, and impact on quality of life of psoriasis are reviewed.
Journal ArticleDOI
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter,Stephen K. Tyring,Kenneth B. Gordon,Alexa B. Kimball,Craig L. Leonardi,Richard G. Langley,Bruce Strober,Martin Kaul,Yihua Gu,Martin M. Okun,Kim A. Papp +10 more
TL;DR: Adalimumab is efficacious and well-tolerated in the treatment of chronic plaque psoriasis and investigating continuous versus interrupted therapy and limitations are limitations.
Journal ArticleDOI
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G. Krueger,Richard G. Langley,Craig L. Leonardi,Newman Yeilding,Cynthia Guzzo,Y. Wang,Lisa T. Dooley,Mark Lebwohl +7 more
TL;DR: This double-blind, placebo-controlled trial demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleUKin- 12/23 p40 cytokines in the pathophysiology of Psoriasis.
Journal ArticleDOI
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
Jean-Hilaire Saurat,Georg Stingl,L. Dubertret,Kim A. Papp,Richard G. Langley,J-P. Ortonne,K. Unnebrink,M. Kaul,A. Camez +8 more
TL;DR: This data indicates that once-weekly dosing with adalimumab is a safe and effective treatment for moderate to severe chronic plaque psoriasis in women with atypical immune response to chemotherapy.